A Study of Avastin (Bevacizumab) in Combination With XELOX in Patients With Metastatic Colorectal Cancer
Status:
Completed
Trial end date:
2011-11-01
Target enrollment:
Participant gender:
Summary
This single arm study will assess the resection rate of liver metastasis, time to disease
progression, and safety of neoadjuvant treatment with Avastin in combination with oxaliplatin
and capecitabine (XELOX) in patients with metastatic colorectal cancer with unresectable
liver metastasis. Patients will receive Avastin 5mg/kg iv on day 1 of every 2 week cycle,
oxaliplatin 85mg/m2 iv on day 1 of every 2 week cycle, and capecitabine 1000mg/m2 on days 1-5
and 8-12 of every 2 week cycle. The anticipated time on study treatment is 3-12 months, and
the target sample size is <100 individuals.